46
Participants
Start Date
January 31, 2012
Primary Completion Date
November 3, 2020
Study Completion Date
November 3, 2020
(Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles
Patients will be treated with cetuximab or panitumumab. Two \[18F-\]-FDG PET-CT will be performed to explore early response. Patients will undergo blood sampling and two skin and tumor biopsies for kinase activity profiles.
VU University Medical Center, Amsterdam
Radboud University Medical Center
OTHER
Jeroen Bosch Ziekenhuis
OTHER
Leiden University Medical Center
OTHER
NKI-AvL
UNKNOWN
Academisch Ziekenhuis Groningen
OTHER
Amsterdam UMC, location VUmc
OTHER